BR112021008094A2 - Methods of treating chronic kidney disease with dapagliflozin - Google Patents
Methods of treating chronic kidney disease with dapagliflozinInfo
- Publication number
- BR112021008094A2 BR112021008094A2 BR112021008094A BR112021008094A BR112021008094A2 BR 112021008094 A2 BR112021008094 A2 BR 112021008094A2 BR 112021008094 A BR112021008094 A BR 112021008094A BR 112021008094 A BR112021008094 A BR 112021008094A BR 112021008094 A2 BR112021008094 A2 BR 112021008094A2
- Authority
- BR
- Brazil
- Prior art keywords
- dapagliflozin
- methods
- kidney disease
- chronic kidney
- treating chronic
- Prior art date
Links
- 208000020832 chronic kidney disease Diseases 0.000 title abstract 4
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 title abstract 3
- 229960003834 dapagliflozin Drugs 0.000 title abstract 3
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
métodos de tratamento de doença renal crônica com dapagliflozina. a presente invenção refere-se a métodos de tratamento de pacientes com doença renal crônica (ckd), com e sem diabetes tipo 2, com um inibidor de sglt2, tal como dapagliflozina.methods of treating chronic kidney disease with dapagliflozin. The present invention relates to methods of treating patients with chronic kidney disease (CKD), with and without type 2 diabetes, with an sglt2 inhibitor, such as dapagliflozin.
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063057139P | 2020-07-27 | 2020-07-27 | |
| US202063070869P | 2020-08-27 | 2020-08-27 | |
| US202063082524P | 2020-09-24 | 2020-09-24 | |
| US202063093961P | 2020-10-20 | 2020-10-20 | |
| US202063119711P | 2020-12-01 | 2020-12-01 | |
| US202163152445P | 2021-02-23 | 2021-02-23 | |
| US202163161629P | 2021-03-16 | 2021-03-16 | |
| PCT/EP2021/058727 WO2022022865A1 (en) | 2020-07-27 | 2021-04-01 | Methods of treating chronic kidney disease with dapagliflozin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021008094A2 true BR112021008094A2 (en) | 2022-02-22 |
Family
ID=79551924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021008094A BR112021008094A2 (en) | 2020-07-27 | 2021-04-01 | Methods of treating chronic kidney disease with dapagliflozin |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP4188389A1 (en) |
| JP (1) | JP2023536009A (en) |
| KR (2) | KR20230149329A (en) |
| CN (3) | CN116392472A (en) |
| AU (2) | AU2021202643B2 (en) |
| BR (1) | BR112021008094A2 (en) |
| CA (1) | CA3116533A1 (en) |
| CR (1) | CR20210222A (en) |
| DO (1) | DOP2021000083A (en) |
| IL (1) | IL282665A (en) |
| JO (1) | JOP20210087A1 (en) |
| MX (1) | MX2021005191A (en) |
| PE (1) | PE20231306A1 (en) |
-
2021
- 2021-04-01 KR KR1020237034971A patent/KR20230149329A/en active Search and Examination
- 2021-04-01 EP EP21716724.6A patent/EP4188389A1/en active Pending
- 2021-04-01 CN CN202310547700.1A patent/CN116392472A/en active Pending
- 2021-04-01 AU AU2021202643A patent/AU2021202643B2/en active Active
- 2021-04-01 BR BR112021008094A patent/BR112021008094A2/en unknown
- 2021-04-01 MX MX2021005191A patent/MX2021005191A/en unknown
- 2021-04-01 CN CN202210071080.4A patent/CN114209689B/en active Active
- 2021-04-01 CN CN202180001003.5A patent/CN114630682A/en active Pending
- 2021-04-01 PE PE2021000657A patent/PE20231306A1/en unknown
- 2021-04-01 JP JP2021523830A patent/JP2023536009A/en active Pending
- 2021-04-01 CA CA3116533A patent/CA3116533A1/en active Pending
- 2021-04-01 JO JOP/2021/0087A patent/JOP20210087A1/en unknown
- 2021-04-01 KR KR1020217013222A patent/KR20220097854A/en not_active IP Right Cessation
- 2021-04-01 CR CR20210222A patent/CR20210222A/en unknown
- 2021-04-26 IL IL282665A patent/IL282665A/en unknown
- 2021-05-03 DO DO2021000083A patent/DOP2021000083A/en unknown
-
2023
- 2023-04-24 AU AU2023202490A patent/AU2023202490A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021202643B2 (en) | 2023-02-02 |
| MX2021005191A (en) | 2022-04-18 |
| JOP20210087A1 (en) | 2023-01-30 |
| EP4188389A1 (en) | 2023-06-07 |
| CN114209689B (en) | 2023-02-17 |
| PE20231306A1 (en) | 2023-08-24 |
| JP2023536009A (en) | 2023-08-23 |
| AU2023202490A1 (en) | 2023-05-11 |
| CN116392472A (en) | 2023-07-07 |
| CN114209689A (en) | 2022-03-22 |
| KR20230149329A (en) | 2023-10-26 |
| CN114630682A (en) | 2022-06-14 |
| CA3116533A1 (en) | 2022-01-27 |
| CR20210222A (en) | 2022-08-29 |
| AU2021202643A1 (en) | 2022-02-10 |
| DOP2021000083A (en) | 2022-04-18 |
| KR20220097854A (en) | 2022-07-08 |
| IL282665A (en) | 2021-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121203T1 (en) | THERAPEUTIC USES OF EMPAGLIFLOSINE | |
| BRPI0606542A2 (en) | methods to increase disease progression time (ttp) or survival, use of a her dimerization inhibitor and use of pertuzumab | |
| CY1120079T1 (en) | Aqueous Composition Containing Bromexine | |
| AR061230A1 (en) | EXTENSION OF THE SURVIVAL OF PATIENTS WITH CANCER WITH HIGH LEVELS OF EGF OR TGF-ALFA | |
| CY1117033T1 (en) | TREATMENT AGAINST ACUTE LEMBLASTIC LEFT | |
| CO2019004034A2 (en) | Pyridine compound | |
| EA201300242A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED ACYLANILIDES | |
| BRPI0507968A (en) | oxidation of organic compounds at high ph | |
| EA033286B1 (en) | Method of treating or delaying the progression of chronic kidney disease | |
| BRPI0911383A2 (en) | alpha helix mimetics and related methods | |
| MX2020010004A (en) | Therapeutic uses of empagliflozin. | |
| EA201000673A1 (en) | METHODS AND COMPOSITIONS FOR MEASURING THE ACTIVATION OF Wnt AND FOR TREATING Wnt-MEDIATED CANCER DISEASES | |
| PH12018502593A1 (en) | Combinations of linagliptin and metformin | |
| EA201170349A1 (en) | MIF MODULATORS | |
| CL2023001351A1 (en) | Methods of treating heart failure by administering omecamtiv mecarbil. | |
| EA200901080A1 (en) | NEW NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF VIRAL INFECTIONS | |
| CL2023000699A1 (en) | Angioedema treatments | |
| PH12020551076A1 (en) | Methods for treating diabetes, hepatitis, and/or inflammatory liver disease | |
| EA200702336A1 (en) | APPLICATION 24-NorUDK | |
| BR112019003946A2 (en) | antitumor agent, antitumor effect booster and antitumor kit | |
| CL2021001097A1 (en) | Methods of treating chronic kidney disease with dapagliflozin | |
| CO2023018381A2 (en) | Improvements in or related to organic compounds | |
| EP4279925A3 (en) | Dulaglutide for the treatment of chronic kidney disease | |
| BR112021008094A2 (en) | Methods of treating chronic kidney disease with dapagliflozin | |
| AR121738A1 (en) | METHODS OF TREATMENT OF CHRONIC KIDNEY DISEASE WITH DAPAGLIFLOZIN |